oliclinomel n5-800 e 1500 ml iv emulsion for infusion with electrolytes bag
baxter healthcare pty ltd - soya oil; olive oil - injection, intravenous infusion - excipient ingredients: sodium oleate; glycerol; sodium hydroxide; egg lecithin; water for injections; ascorbyl palmitate - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
oliclinomel n5-800 1500ml iv emulsion for infusion without electrolytes bag
baxter healthcare pty ltd - soya oil; olive oil - injection, intravenous infusion - excipient ingredients: sodium hydroxide; sodium oleate; egg lecithin; water for injections; ascorbyl palmitate; glycerol - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
oliclinomel n4-550 e 1500 ml iv emulsion for infusion with electrolytes bag
baxter healthcare pty ltd - soya oil; olive oil - injection, intravenous infusion - excipient ingredients: glycerol; sodium hydroxide; ascorbyl palmitate; egg lecithin; water for injections; sodium oleate - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
oliclinomel n4-550 1500 ml iv emulsion for infusion without electrolytes bag
baxter healthcare pty ltd - soya oil; olive oil - injection, intravenous infusion - excipient ingredients: glycerol; sodium hydroxide; water for injections; sodium oleate; egg lecithin; ascorbyl palmitate - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
oliclinomel n7-1000 1000ml iv emulsion for infusion without electrolytes bag
baxter healthcare pty ltd - soya oil; olive oil - injection, intravenous infusion - excipient ingredients: glycerol; water for injections; ascorbyl palmitate; sodium oleate; sodium hydroxide; egg lecithin - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
oliclinomel n6-900 e 1000ml iv emulsion for infusion with electrolytes bag
baxter healthcare pty ltd - soya oil; olive oil - injection, intravenous infusion - excipient ingredients: egg lecithin; water for injections; sodium hydroxide; glycerol; sodium oleate; ascorbyl palmitate - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
oliclinomel n6-900 1000ml iv emulsion for infusion without electrolytes bag
baxter healthcare pty ltd - soya oil; olive oil - injection, intravenous infusion - excipient ingredients: sodium hydroxide; egg lecithin; sodium oleate; glycerol; ascorbyl palmitate; water for injections - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
oliclinomel n5-800 e 1000ml iv emulsion for infusion with electrolytes bag
baxter healthcare pty ltd - soya oil; olive oil - injection, intravenous infusion - excipient ingredients: sodium oleate; glycerol; ascorbyl palmitate; egg lecithin; water for injections; sodium hydroxide - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
oliclinomel n5-800 1000ml iv emulsion for infusion without electrolytes bag
baxter healthcare pty ltd - soya oil; olive oil - injection, intravenous infusion - excipient ingredients: egg lecithin; sodium hydroxide; sodium oleate; water for injections; ascorbyl palmitate; glycerol - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.
soliris eculizumab (rmc) 300 mg/30 ml concentrated solution for intravenous infusion vial
alexion pharmaceuticals australasia pty ltd - eculizumab, quantity: 300 mg - injection, intravenous infusion - excipient ingredients: polysorbate 80; sodium chloride; water for injections; dibasic sodium phosphate heptahydrate; monobasic sodium phosphate monohydrate - soliris is indicated for the treatment of patients with: ? paroxysmal nocturnal haemoglobinuria (pnh) to reduce haemolysis. ? atypical haemolytic uraemic syndrome (ahus). ? adult patients with neuromyelitis optica spectrum disorder (nmosd) who are anti-aquaporin-4 (aqp4) antibody-positive. soliris is not intended for acute treatment of a nmosd relapse.